Share This Article:

Can we achieve complete remission in locally advanced unresectable Hepatocellular Carcinoma (HCC) by using Sorafenib? Case report and review of literature from Qatar

DOI: 10.4236/mc.2012.11001    3,493 Downloads   7,672 Views   Citations

ABSTRACT

Patients with HCC continue to have a dismal prognosis, with 1-year and 3-year survival rates of 36 and 17%, respectively. This is in part related to more than two-thirds of tumors being diagnosed at advanced stages, as well as a substantial portion of patients with early HCC failing to receive potentially curative treatments. Systemic therapy for advanced unresectable HCC limited until the discovery of sorafenib, we are reporting a 53 year patient with unresectable HCC achieved complete remission clinically, radiologically and biochemically with sorafenib which is the first case report.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Rasul, K. (2012) Can we achieve complete remission in locally advanced unresectable Hepatocellular Carcinoma (HCC) by using Sorafenib? Case report and review of literature from Qatar. Modern Chemotherapy, 1, 1-4. doi: 10.4236/mc.2012.11001.

References

[1] El-Serag, H.B., Siegel, A.B., Davila, J.A., et al. (2006) Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: A population-based study. Journal of Hepatology, 44, 158-166. doi:10.1016/j.jhep.2005.10.002
[2] Josep, M. Llovet, M.D., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., et al. (2008) Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine, 359, 378-390. doi:10.1056/NEJMoa0708857
[3] Cheng, A.L., Kang, Y.K., Chen, Z., Tsao, C.J., et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. The Lancet Oncology, 10, 25-34. doi:10.1016/S1470-2045(08)70285-7
[4] Forner, A., Hessheimer, A.J., Isabel Real, M., et al. (2006) Treatment of hepatocellular carcinoma. Critical Reviews in Oncology/Hematology, 60, 89-98. doi:10.1016/j.critrevonc.2006.06.001
[5] Okuda, K. (2000) Hepatocellular carcinoma. Journal of Hepatology, 32, 225-237. doi:10.1016/S0168-8278(00)80428-6
[6] Llovet, J.M., Bustamante, J., Castells, A., et al. (1999) Natural history of unresected nonsurgical hepatocellular carcinoma for the design and evaluation of therapeutic trials. Hepatology, 29, 62-67. doi:10.1002/hep.510290145
[7] Okuda, K., Takayasu, K., Okada, S. (1997) Treatment selection. In: Okuda, K. and Tabor, E. Eds., Liver Cancer, Churchill-Livingstone, New York, 435-439.

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.